The Pharmacology of Lymphocytes

1. Part 3

   1. Thymic Hormones and Lymphocyte Functions

      • J.-F. Bach, M. Dardenne

      Pages 415-421

2. Part 4

   1. Front Matter

      Pages 423-423

      PDF

   2. Glucocorticosteroids

      • T. W. Behrens, J. S. Goodwin

      Pages 425-439

   3. Slow Acting Antirheumatics

      • P. E. Lipsky

      Pages 441-452

   4. Cyclophosphamide

      • R. R. Bartlett

      Pages 453-469

   5. Lobenzarit (CCA)

      • Y. Shiokawa

      Pages 471-486

   6. Cyclosporins: Immunopharmacologic Properties of Natural Cyclosporins

      • P. C. Hiestand, H. U. Gubler

      Pages 487-502

   7. Muramyl Dipeptides

      • M. Parant, L. Chedid

      Pages 503-516

   8. Antipurines and Purine Metabolism

      • G. Wolberg

      Pages 517-533

   9. Isoprinosine and NPT 15392: Hypoxanthine-Containing Immunomodulators

      • J. Gordon, Th. Ginsberg

      Pages 535-553

   10. Bacterial and Fungal Products

       • H. Takada, J. Hamuro, S. Kotani

       Pages 555-575

   11. Nonsteroidal Anti-inflammatory Drugs: Effects on Lymphocyte Function

       • K. Brune

       Pages 577-585

   12. Future Prospects for Drug Design of Lymphocyte Modulators

       • J. Drews, W. Haas

       Pages 587-610

3. Back Matter

   Pages 611-628

   PDF

"Immunopharmacology" , why not "pharmacoimmunology"? Professor H. O. Schild University College London, 1962 An intact immune response is essential for survival, as is evidenced by the various innate immune deficiency syndromes and by the emergence of the acquired immune deficiency syndrome (AIDS) as a pandemic during the last decade. Substances which stimulate the immune response might contribute to the therapy of AIDS and its precursor, AIDS-related syndrome, as well as of other clinical conditions in which immune responses can be diminished, such as carcinoma and infections. In other circumstances, an intact or heightened immune response may pose clinical problems; hence there is need to suppress, or diminish, components of the immune response. For instance, it is necessary to impair cellular immunity in order to ensure lasting acceptance of heterografts and it is already established that agents effective in transplantation are therapeutically effective in an range of autoimmune diseases. More recently, experimental studies have indicated that aberrant manifestations of humoral immunity, as in allergies, may also be amenable to pharmacological intervention.

• biochemistry
• immunology
• immunotherapy
• lymphocytes
• pharmacology

• Research Department, CIBA-GEIGY AG, Basel, Switzerland

  Michael A. Bray

• Pharmaceutical Division, Preclinical Research, SANDOZ Ltd., Basel, Switzerland

  John Morley

Policies and ethics